Epitope of parainfluenza virus type 5 F protein, monoclonal antibody and application

By identifying the 135-157 epitopes of the PIV5 F protein and preparing monoclonal antibodies, the technical bottlenecks in PIV5 vaccine design and diagnostic methods have been overcome, achieving a technological breakthrough in highly specific diagnosis and vaccine development.

CN122145588APending Publication Date: 2026-06-05HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)
0 Cites 0 Cited by

Patent Information

Application Number
CN202610291844.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-11
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

The existing technology has limited understanding of the biological functions of parainfluenza virus type 5 (PIV5) F protein and lacks systematic identification of antigenic epitopes, which affects the development of vaccine design and diagnostic methods.

Method used

The core antigenic epitope of the PIV5 F protein was determined to be amino acids 135-157 using overlapping peptide scanning technology. Monoclonal antibodies were designed and prepared, and key residues were verified by site-directed mutagenesis analysis. Highly specific ELISA diagnostic kits and multi-epitope vaccines were developed.

Benefits of technology

This study provides novel targets and vaccine design strategies for PIV5 diagnostic kits, overcoming the high cost and large batch-to-batch variability issues associated with traditional monoclonal antibody preparation, and ensuring the specificity and functionality of the antibodies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an antigen epitope of parainfluenza virus type 5 F protein, a monoclonal antibody and application, relates to the technical field of biology, and provides the antigen epitope of the parainfluenza virus type 5 F protein, which is 135AAILNLKNAIQKTNAAVADVVQA157. The invention also provides a monoclonal antibody capable of specifically recognizing the antigen epitope. The amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1 in a sequence table, and the amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.2 in the sequence table. The discovery of the epitope provides a new target for research and development of a PIV5 diagnostic reagent, peptide antigens can be designed and synthesized based on the epitope, and a high-specificity ELISA diagnostic kit can be developed; meanwhile, the epitope can be used as a candidate epitope for design of multi-epitope vaccines, and a new strategy is provided for prevention and control of PIV5.
Need to check novelty before this filing date? Find Prior Art